Name
Merus N.V.
Company Description
The product candidates in the Merus pipeline are based on the Multiclonics® format (full length human IgG antibodies). Our strategy employs the unique attributes of our proprietary bispecific antibodies and our patented screening technologies to engage and harness the power of the immune system to target tumor cells.
Website
Address (city, state, and country will display online and in-print)
Cambridge, MA
United States
United States
Listings
Relevance
